eptacog alfa activated

The drug is used for the treatment and prevention of bleeding during surgical interventions or other invasive procedures in patients with congenital hemophilia (with or without inhibitors), acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. It is also indicated for the treatment of severe postpartum hemorrhage if standard therapy is ineffective.

Form: powder, lyophilized for injection solution

ATC: B02BD08

Manufacturer: A/S Novo Nordisk (Responsible for batch release of finished product; manufacturing unit conducting control/testing of finished product batch; manufacturing unit conducting secondary packaging of finished product; manufacturing unit conducting production of unpackaged product, filtration, filling, and lyophilization of powder)

The drug is used for the treatment and prevention of bleeding during surgical interventions or other invasive procedures in patients with congenital hemophilia (with the presence of inhibitors or an exaggerated response to factors VIII or IX), acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. It is also indicated for the treatment of severe postpartum hemorrhage if standard therapy is ineffective.

Form: powder, lyophilized for injection solution

ATC: B02BD08

Manufacturer: A/S Novo Nordisk (responsible for batch release of finished product; manufacturing site where batch testing/inspection is conducted; manufacturing site where secondary packaging of finished product is performed; manufacturing site where unpackaged product production, filtration, filling, and lyophilization of powder are carried out)